Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial.

Barbour AP, Walpole ET, Mai GT, Barnes EH, Watson DI, Ackland SP, Martin JM, Burge M, Finch R, Karapetis CS, Shannon J, Nott LM, Varma S, Marx G, Falk GL, Gebski V, Oostendorp M, Wilson K, Thomas J, Lampe G, Zalcberg JR, Simes J, Smithers BM; DOCTOR investigators.

Ann Oncol. 2020 Feb;31(2):236-245. doi: 10.1016/j.annonc.2019.10.019. Epub 2019 Dec 23.

PMID:
31959340
2.

Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial.

Olafson LR, Siddell AH, Field KM, Byrnes M, Rapkins RW, Ng B, Nixdorf S, Barnes EH, Johns TG, Yip S, Simes J, Nowak AK, Rosenthal MA, McDonald KL.

J Clin Neurosci. 2019 Dec;70:157-163. doi: 10.1016/j.jocn.2019.08.044. Epub 2019 Sep 30.

PMID:
31582283
3.

Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer.

Dauzier E, Lacas B, Blanchard P, Le QT, Simon C, Wolf G, Janot F, Horiuchi M, Tobias JS, Moon J, Simes J, Deshmane V, Mazeron JJ, Mehta S, Zaktonik B, Tamura M, Moyal E, Licitra L, Fortpied C, Haffty BG, Ghi MG, Gregoire V, Harris J, Bourhis J, Aupérin A, Pignon JP; MACH-NC Collaborative Group.

Oral Oncol. 2019 Aug;95:106-114. doi: 10.1016/j.oraloncology.2019.06.001. Epub 2019 Jun 15.

PMID:
31345376
4.

Changes in plasma lipids predict pravastatin efficacy in secondary prevention.

Jayawardana KS, Mundra PA, Giles C, Barlow CK, Nestel PJ, Barnes EH, Kirby A, Thompson P, Sullivan DR, Alshehry ZH, Mellett NA, Huynh K, McConville MJ, Zoungas S, Hillis GS, Chalmers J, Woodward M, Marschner IC, Wong G, Kingwell BA, Simes J, Tonkin AM, Meikle PJ; LIPID Study Investigators.

JCI Insight. 2019 Jul 11;4(13). pii: 128438. doi: 10.1172/jci.insight.128438. eCollection 2019 Jul 11.

5.

Drug use in the year after prison.

Western B, Simes JT.

Soc Sci Med. 2019 Aug;235:112357. doi: 10.1016/j.socscimed.2019.112357. Epub 2019 Jun 8.

PMID:
31221441
6.

Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.

Hilvo M, Meikle PJ, Pedersen ER, Tell GS, Dhar I, Brenner H, Schöttker B, Lääperi M, Kauhanen D, Koistinen KM, Jylhä A, Huynh K, Mellett NA, Tonkin AM, Sullivan DR, Simes J, Nestel P, Koenig W, Rothenbacher D, Nygård O, Laaksonen R.

Eur Heart J. 2020 Jan 14;41(3):371-380. doi: 10.1093/eurheartj/ehz387.

PMID:
31209498
7.

Response by Simes et al to Letter Regarding Article, "D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease".

Simes J, Kirby A, Tonkin A.

Circulation. 2019 Feb 26;139(9):1245-1246. doi: 10.1161/CIRCULATIONAHA.118.038480. No abstract available.

PMID:
30857403
8.

Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20.

Wells JC, Tu D, Siu LL, Shapiro JD, Jonker DJ, Karapetis C, Simes J, Liu G, Price TJ, Tebbutt NC, O'Callaghan CJ.

Clin Colorectal Cancer. 2019 Mar;18(1):e140-e149. doi: 10.1016/j.clcc.2018.11.006. Epub 2018 Nov 28.

PMID:
30595557
9.

Anti-angiogenic therapy for high-grade glioma.

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M.

Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218. doi: 10.1002/14651858.CD008218.pub4.

10.

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.

Shapiro JD, Thavaneswaran S, Underhill CR, Robledo KP, Karapetis CS, Day FL, Nott LM, Jefford M, Chantrill LA, Pavlakis N, Tebbutt NC, Price TJ, Khasraw M, Van Hazel GA, Waring PM, Tejpar S, Simes J, Gebski VJ, Desai J, Segelov E.

Clin Colorectal Cancer. 2018 Dec;17(4):313-319. doi: 10.1016/j.clcc.2018.06.002. Epub 2018 Jun 8.

PMID:
30463680
11.

Pulse Oximeter Saturation Targeting and Oximeter Changes in the Benefits of Oxygen Saturation Targeting (BOOST)-II Australia and BOOST-II UK Oxygen Trials.

Stenson BJ, Donoghoe M, Brocklehurst P, Davis PG, Juszczak E, Marschner IC, Simes J, Tarnow-Mordi WO.

J Pediatr. 2019 Jan;204:301-304.e2. doi: 10.1016/j.jpeds.2018.08.033. Epub 2018 Oct 9.

PMID:
30314661
12.

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.

Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S.

Lancet. 2018 Oct 13;392(10155):1311-1320. doi: 10.1016/S0140-6736(18)31652-0. Epub 2018 Oct 4.

PMID:
30293769
13.

Disease-free Survival and Local Recurrence After Laparoscopic-assisted Resection or Open Resection for Rectal Cancer: The Australasian Laparoscopic Cancer of the Rectum Randomized Clinical Trial.

Stevenson ARL, Solomon MJ, Brown CSB, Lumley JW, Hewett P, Clouston AD, Gebski VJ, Wilson K, Hague W, Simes J; Australasian Gastro-Intestinal Trials Group (AGITG) ALaCaRT investigators.

Ann Surg. 2019 Apr;269(4):596-602. doi: 10.1097/SLA.0000000000003021.

PMID:
30247332
14.

Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).

Mersiades AJ, Tognela A, Haber PS, Stockler M, Lintzeris N, Simes J, McGregor I, Olver I, Allsop DJ, Gedye C, Kirby AC, Morton RL, Fox P, Clarke S, Briscoe K, Aghmesheh M, Wong N, Walsh A, Hahn C, Grimison P.

BMJ Open. 2018 Sep 12;8(9):e020745. doi: 10.1136/bmjopen-2017-020745.

15.

Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention.

Mundra PA, Barlow CK, Nestel PJ, Barnes EH, Kirby A, Thompson P, Sullivan DR, Alshehry ZH, Mellett NA, Huynh K, Jayawardana KS, Giles C, McConville MJ, Zoungas S, Hillis GS, Chalmers J, Woodward M, Wong G, Kingwell BA, Simes J, Tonkin AM, Meikle PJ; LIPID Study Investigators.

JCI Insight. 2018 Sep 6;3(17). pii: 121326. doi: 10.1172/jci.insight.121326. eCollection 2018 Sep 6.

16.

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.

Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R.

Neuro Oncol. 2019 Jan 1;21(1):106-114. doi: 10.1093/neuonc/noy091.

17.

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.

Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y, Tebbutt NC, Markman B, Price T, Esaki T, Koski S, Hitron M, Li W, Li Y, Magoski NM, Li CJ, Simes J, Tu D, O'Callaghan CJ.

Lancet Gastroenterol Hepatol. 2018 Apr;3(4):263-270. doi: 10.1016/S2468-1253(18)30009-8. Epub 2018 Feb 1.

PMID:
29397354
18.

D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease.

Simes J, Robledo KP, White HD, Espinoza D, Stewart RA, Sullivan DR, Zeller T, Hague W, Nestel PJ, Glasziou PP, Keech AC, Elliott J, Blankenberg S, Tonkin AM; LIPID Study Investigators.

Circulation. 2018 Aug 14;138(7):712-723. doi: 10.1161/CIRCULATIONAHA.117.029901.

PMID:
29367425
19.

When do patient reported quality of life indicators become prognostic in breast cancer?

Lee CK, Hudson M, Simes J, Ribi K, Bernhard J, Coates AS.

Health Qual Life Outcomes. 2018 Jan 12;16(1):13. doi: 10.1186/s12955-017-0834-2.

20.

Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial.

Field KM, Fitt G, Rosenthal MA, Simes J, Nowak AK, Barnes EH, Sawkins K, Goh C, Moffat BA, Salinas S, Cher L, Wheeler H, Hovey EJ, Phal PM; CABARET/COGNO Investigators.

Asia Pac J Clin Oncol. 2018 Oct;14(5):e359-e365. doi: 10.1111/ajco.12806. Epub 2017 Nov 8.

PMID:
29114999
21.

Delayed vs early umbilical cord clamping for preterm infants: a systematic review and meta-analysis.

Fogarty M, Osborn DA, Askie L, Seidler AL, Hunter K, Lui K, Simes J, Tarnow-Mordi W.

Am J Obstet Gynecol. 2018 Jan;218(1):1-18. doi: 10.1016/j.ajog.2017.10.231. Epub 2017 Oct 30. Review.

PMID:
29097178
22.

Delayed versus Immediate Cord Clamping in Preterm Infants.

Tarnow-Mordi W, Morris J, Kirby A, Robledo K, Askie L, Brown R, Evans N, Finlayson S, Fogarty M, Gebski V, Ghadge A, Hague W, Isaacs D, Jeffery M, Keech A, Kluckow M, Popat H, Sebastian L, Aagaard K, Belfort M, Pammi M, Abdel-Latif M, Reynolds G, Ariff S, Sheikh L, Chen Y, Colditz P, Liley H, Pritchard M, de Luca D, de Waal K, Forder P, Duley L, El-Naggar W, Gill A, Newnham J, Simmer K, Groom K, Weston P, Gullam J, Patel H, Koh G, Lui K, Marlow N, Morris S, Sehgal A, Wallace E, Soll R, Young L, Sweet D, Walker S, Watkins A, Wright I, Osborn D, Simes J; Australian Placental Transfusion Study Collaborative Group.

N Engl J Med. 2017 Dec 21;377(25):2445-2455. doi: 10.1056/NEJMoa1711281. Epub 2017 Oct 29.

23.

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.

van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. doi: 10.1007/s00280-017-3451-1. Epub 2017 Oct 26.

24.

Cancer multidisciplinary team meetings in practice: Results from a multi-institutional quantitative survey and implications for policy change.

Rankin NM, Lai M, Miller D, Beale P, Spigelman A, Prest G, Turley K, Simes J.

Asia Pac J Clin Oncol. 2018 Feb;14(1):74-83. doi: 10.1111/ajco.12765. Epub 2017 Sep 26.

PMID:
28949100
25.

Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis.

Herzog S, Shanahan M, Grimison P, Tran A, Wong N, Lintzeris N, Simes J, Stockler M, Morton RL.

Pharmacoeconomics. 2018 Jan;36(1):67-78. doi: 10.1007/s40273-017-0565-6.

PMID:
28866778
26.

Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial.

Hovey EJ, Field KM, Rosenthal MA, Barnes EH, Cher L, Nowak AK, Wheeler H, Sawkins K, Livingstone A, Phal P, Goh C, Simes J; CABARET/COGNO investigators.

Neurooncol Pract. 2017 Sep;4(3):171-181. doi: 10.1093/nop/npw025. Epub 2017 May 25.

27.

Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma.

Martin AJ, Gibbs E, Sjoquist K, Pavlakis N, Simes J, Price T, Shannon J, Gill S, Jain V, Liu G, Kannourakis G, Kim YH, Kim JW, Goldstein D; INTEGRATE I investigators.

Gastric Cancer. 2018 May;21(3):473-480. doi: 10.1007/s10120-017-0754-1. Epub 2017 Aug 16.

PMID:
28815316
28.

Predictors of incident heart failure in patients after an acute coronary syndrome: The LIPID heart failure risk-prediction model.

Driscoll A, Barnes EH, Blankenberg S, Colquhoun DM, Hunt D, Nestel PJ, Stewart RA, West MJ, White HD, Simes J, Tonkin A.

Int J Cardiol. 2017 Dec 1;248:361-368. doi: 10.1016/j.ijcard.2017.06.098. Epub 2017 Jun 30.

PMID:
28728851
29.

The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET).

Field KM, Phal PM, Fitt G, Goh C, Nowak AK, Rosenthal MA, Simes J, Barnes EH, Sawkins K, Cher LM, Hovey EJ, Wheeler H.

Cancer. 2017 Sep 15;123(18):3576-3582. doi: 10.1002/cncr.30838. Epub 2017 Jul 5.

30.

Persistent psychological distress and mortality in patients with stable coronary artery disease.

Stewart RAH, Colquhoun DM, Marschner SL, Kirby AC, Simes J, Nestel PJ, Glozier N, O'Neil A, Oldenburg B, White HD, Tonkin AM; LIPID Study Investigators.

Heart. 2017 Dec;103(23):1860-1866. doi: 10.1136/heartjnl-2016-311097. Epub 2017 Jun 26.

PMID:
28652315
31.

Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study.

Ong KL, O'Connell R, Januszewski AS, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, Waldman B, Colman PG, Best JD, Simes JR, Rye KA, Keech AC; FIELD study investigators.

Clin Chem. 2017 Jul;63(7):1261-1270. doi: 10.1373/clinchem.2016.270876. Epub 2017 Jun 12.

PMID:
28606915
32.

Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma.

Field KM, King MT, Simes J, Espinoza D, Barnes EH, Sawkins K, Rosenthal MA, Cher L, Hovey E, Wheeler H, Nowak AK.

J Neurooncol. 2017 Jul;133(3):623-631. doi: 10.1007/s11060-017-2479-8. Epub 2017 May 22.

PMID:
28534153
33.

TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.

Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, Zalcberg J, Boussioutas A, Findlay M, O'Connell RL, Verghis J, Willis D, Kron T, Crain M, Murray WK, Lordick F, Swallow C, Darling G, Simes J, Wong R.

Ann Surg Oncol. 2017 Aug;24(8):2252-2258. doi: 10.1245/s10434-017-5830-6. Epub 2017 Mar 23.

PMID:
28337660
34.

Histomorphologic and ultrastructural recovery of myopathy in rats treated with low-level laser therapy.

Servetto N, Cremonezzi D, Simes JC, Di Pietro A, Campana VR.

Lasers Med Sci. 2017 May;32(4):841-849. doi: 10.1007/s10103-017-2182-1. Epub 2017 Mar 9.

PMID:
28280999
35.

Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? Five-Year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial: Assessment and Incidence of True Lymphedema.

Wetzig N, Gill PG, Espinoza D, Mister R, Stockler MR, Gebski VJ, Ung OA, Campbell I, Simes J.

Ann Surg Oncol. 2017 Apr;24(4):1064-1070. doi: 10.1245/s10434-016-5669-2. Epub 2016 Nov 15.

PMID:
27848050
36.

Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus.

Alshehry ZH, Mundra PA, Barlow CK, Mellett NA, Wong G, McConville MJ, Simes J, Tonkin AM, Sullivan DR, Barnes EH, Nestel PJ, Kingwell BA, Marre M, Neal B, Poulter NR, Rodgers A, Williams B, Zoungas S, Hillis GS, Chalmers J, Woodward M, Meikle PJ.

Circulation. 2016 Nov 22;134(21):1637-1650. Epub 2016 Oct 18.

37.

Interpretation of the evidence for the efficacy and safety of statin therapy.

Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R.

Lancet. 2016 Nov 19;388(10059):2532-2561. doi: 10.1016/S0140-6736(16)31357-5. Epub 2016 Sep 8. Review. Erratum in: Lancet. 2017 Feb 11;389(10069):602.

38.

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.

Cholesterol Treatment Trialists' (CTT) Collaboration, Herrington WG, Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu MD, Mark PB, Fellström B, Jardine AG, Wanner C, Holdaas H, Fulcher J, Haynes R, Landray MJ, Keech A, Simes J, Collins R, Baigent C.

Lancet Diabetes Endocrinol. 2016 Oct;4(10):829-39. doi: 10.1016/S2213-8587(16)30156-5. Epub 2016 Jul 29.

39.

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.

Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D.

J Clin Oncol. 2016 Aug 10;34(23):2728-35. doi: 10.1200/JCO.2015.65.1901. Epub 2016 Jun 20.

40.

Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.

Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O'Callaghan CJ, Zalcberg JR, Karapetis CS, Dobrovic A.

Clin Cancer Res. 2016 May 15;22(10):2435-44. doi: 10.1158/1078-0432.CCR-15-0414.

41.

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.

Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro JD.

J Clin Oncol. 2016 Jul 1;34(19):2258-64. doi: 10.1200/JCO.2015.65.6843. Epub 2016 Apr 25.

PMID:
27114605
42.

Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study.

Hague WE, Simes J, Kirby A, Keech AC, White HD, Hunt D, Nestel PJ, Colquhoun DM, Pater H, Stewart RA, Sullivan DR, Thompson PL, West M, Glasziou PP, Tonkin AM; LIPID study investigators†.

Circulation. 2016 May 10;133(19):1851-60. doi: 10.1161/CIRCULATIONAHA.115.018580. Epub 2016 Mar 25. Review.

PMID:
27016105
43.

Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.

Lee CK, Davies L, Gebski VJ, Lord SJ, Di Leo A, Johnston S, Geyer C Jr, Cameron D, Press MF, Ellis C, Loi S, Marschner I, Simes J, de Souza P.

J Clin Oncol. 2016 Mar 20;34(9):936-44. doi: 10.1200/JCO.2015.62.4767. Epub 2016 Jan 25.

PMID:
26811533
44.

Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial.

Stevenson AR, Solomon MJ, Lumley JW, Hewett P, Clouston AD, Gebski VJ, Davies L, Wilson K, Hague W, Simes J; ALaCaRT Investigators.

JAMA. 2015 Oct 6;314(13):1356-63. doi: 10.1001/jama.2015.12009.

PMID:
26441180
45.

Meta-analysis of radical resection rates and margin assessment in pancreatic cancer.

Chandrasegaram MD, Goldstein D, Simes J, Gebski V, Kench JG, Gill AJ, Samra JS, Merrett ND, Richardson AJ, Barbour AP.

Br J Surg. 2015 Nov;102(12):1459-72. doi: 10.1002/bjs.9892. Epub 2015 Sep 9. Review.

PMID:
26350029
46.

Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study.

Tonkin AM, Blankenberg S, Kirby A, Zeller T, Colquhoun DM, Funke-Kaiser A, Hague W, Hunt D, Keech AC, Nestel P, Stewart R, Sullivan DR, Thompson PL, West M, White HD, Simes J; LIPID study investigators.

Int J Cardiol. 2015 Dec 15;201:499-507. doi: 10.1016/j.ijcard.2015.07.080. Epub 2015 Aug 16.

PMID:
26318511
47.

First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma.

Whittle JR, Lickliter JD, Gan HK, Scott AM, Simes J, Solomon BJ, MacDiarmid JA, Brahmbhatt H, Rosenthal MA.

J Clin Neurosci. 2015 Dec;22(12):1889-94. doi: 10.1016/j.jocn.2015.06.005. Epub 2015 Aug 13.

PMID:
26279503
48.

TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).

Leong T, Smithers BM, Michael M, Gebski V, Boussioutas A, Miller D, Simes J, Zalcberg J, Haustermans K, Lordick F, Schuhmacher C, Swallow C, Darling G, Wong R.

BMC Cancer. 2015 Jul 21;15:532. doi: 10.1186/s12885-015-1529-x.

49.

Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.

Field KM, Simes J, Nowak AK, Cher L, Wheeler H, Hovey EJ, Brown CS, Barnes EH, Sawkins K, Livingstone A, Freilich R, Phal PM, Fitt G; CABARET/COGNO investigators, Rosenthal MA.

Neuro Oncol. 2015 Nov;17(11):1504-13. doi: 10.1093/neuonc/nov104. Epub 2015 Jun 30.

50.

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.

Weickhardt AJ, Williams DS, Lee CK, Chionh F, Simes J, Murone C, Wilson K, Parry MM, Asadi K, Scott AM, Punt CJ, Nagtegaal ID, Price TJ, Mariadason JM, Tebbutt NC.

Br J Cancer. 2015 Jun 30;113(1):37-45.

Supplemental Content

Support Center